Persistent hypocoagulability in patients with septic shock predicts greater hospital mortality: Impact of impaired thrombin generation

Intensive Care Medicine

Volumn 38, Issue 8, 2012, Pages 1326-1335

  Massion, Paul B ^a   Peters, Pierre ^a   Ledoux, Didier ^a   Zimermann, Valentine ^a   Canivet, Jean Luc ^a   Massion, Pierre P ^b   Damas, Pierre ^a   Gothot, André ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticoagulants; Blood coagulation disorders; Disseminated intravascular coagulation; Septic shock; Thrombin; Thromboelastography

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD CLOTTING TEST; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPOCOAGULABILITY; INTENSIVE CARE UNIT; MALE; MORTALITY; PARTIAL THROMBOPLASTIN TIME; SEPTIC SHOCK; THROMBIN TIME;

AGED; ANTICOAGULANTS; ANTITHROMBIN III; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; FEMALE; FIBRIN; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDIES; PROTEIN C; PROTHROMBIN TIME; SHOCK, SEPTIC; THROMBIN;

EID: 84864283806     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-012-2620-2     Document Type: Article

References (42)

1. Amaral A, Opal SM, Vincent JL (2004) Coagulation in sepsis. Intensive Care Med 30:1032-1040 (Pubitemid 38833353)
2. Borgel D, Bornstain C, Reitsma PH, Lerolle N, Gandrille S, Dali-Ali F, Esmon CT, Fagon JY, Aiach M, Diehl JL (2007) A comparative study of the protein C pathway in septic and nonseptic patients with organ failure. Am J Respir Crit Care Med 176:878-885 (Pubitemid 350097077)
3. Monroe DM, Hoffman M (2006) What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 26:41-48 (Pubitemid 43732226)
4. Gando S, Nanzaki S, Sasaki S, Aoi K, Kemmotsu O (1998) Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med 26:2005-2009 (Pubitemid 29016682)
5. Franco RF, de Jonge E, Dekkers PE, Timmerman JJ, Spek CA, van Deventer SJ, van Deursen P, van Kerkhoff L, van Gemen B, ten Cate H, van der Poll T, Reitsma PH (2000) The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood 96:554-559 (Pubitemid 30463375)
6. Degen JL, Bugge TH, Goguen JD (2007) Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost 5(Suppl 1):24-31 (Pubitemid 46958813)
7. Psuja P, Zozulinska M, Turowiecka Z, Cieslikowski W, Vinazzer H, Zawilska K (2002) Plasma markers of hypercoagulability in patients with serious infections and risk of septic shock. Clin Appl Thromb Hemost 8:225-230
8. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290:238-247 (Pubitemid 37430063)
9. Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, Opal S (2011) Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 183:1561-1568
10. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869-1878 (Pubitemid 33010239)
11. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM (2006) High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 34:285-292 (Pubitemid 43145602)
12. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709 (Pubitemid 32204987)
13. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353:1332-1341 (Pubitemid 41362701)
14. Dhainaut JF, Antonelli M, Wright P, Desachy A, Reignier J, Lavoue S, Charpentier J, Belger M, Cobas-Meyer M, Maier C, Mignini MA, Janes J (2009) Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock. Intensive Care Med 35:1187-1195
15. Yamakawa K, Fujimi S, Mohri T, Matsuda H, Nakamori Y, Hirose T, Tasaki O, Ogura H, Kuwagata Y, Hamasaki T, Shimazu T (2011) Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care 15:R123
16. Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Gardlund B, Marshall JC, Rhodes A (2008) Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 34:1935-1947
17. Levi M, Ten Cate H (1999) Disseminated intravascular coagulation. N Engl J Med 341:586-592 (Pubitemid 29384168)
18. Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL (2004) Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 32:1825-1831 (Pubitemid 39202356)
19. van der Poll T, Opal SM (2008) Host-pathogen interactions in sepsis. Lancet Infect Dis 8:32-43
20. Hemker HC, Al Dieri R, De Smedt E, Beguin S (2006) Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 96:553-561 (Pubitemid 44782533)
21. van Veen JJ, Gatt A, Makris M (2008) Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 142:889-903
22. Luddington RJ (2005) Thrombelastography/thromboelastometry. Clin Lab Haematol 27:81-90 (Pubitemid 40515992)
23. Dargaud Y, Lienhart A, Negrier C (2010) Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 116:5734-5737
24. Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM (2008) High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 6:1327-1333 (Pubitemid 352016312)
25. Tripodi A, Branchi A, Chantarangkul V, Clerici M, Merati G, Artoni A, Mannucci PM (2011) Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis 31:165-172
26. Collins PW, Macchiavello LI, Lewis SJ, Macartney NJ, Saayman AG, Luddington R, Baglin T, Findlay GP (2006) Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol 135:220-227 (Pubitemid 44401620)
27. Petros S, Kliem P, Siegemund T, Siegemund R (2012) Thrombin generation in severe sepsis. Thromb Res 129:797-800
28. Gonano C, Sitzwohl C, Meitner E, Weinstabl C, Kettner SC (2006) Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Crit Care 10:R160
29. Daudel F, Kessler U, Folly H, Lienert JS, Takala J, Jakob SM (2009) Thromboelastometry for the assessment of coagulation abnormalities in early and established adult sepsis: a prospective cohort study. Crit Care 13:R42
30. Adamzik M, Eggmann M, Frey UH, Gorlinger K, Brocker-Preuss M, Marggraf G, Saner F, Eggebrecht H, Peters J, Hartmann M (2010) Comparison of thromboelastometry with procalcitonin, interleukin 6, and C-reactive protein as diagnostic tests for severe sepsis in critically ill adults. Crit Care 14:R178
31. Adamzik M, Langemeier T, Frey UH, Gorlinger K, Saner F, Eggebrecht H, Peters J, Hartmann M (2011) Comparison of thrombelastometry with simplified acute physiology score II and sequential organ failure assessment scores for the prediction of 30-day survival: a cohort study. Shock 35:339-342
32. Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre PF, Dhainaut JF (2004) Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism ISRCTN74215569. Crit Care 8:R82-R90
33. Russell JA, Singer J, Bernard GR, Wheeler A, Fulkerson W, Hudson L, Schein R, Summer W, Wright P, Walley KR (2000) Changing pattern of organ dysfunction in early human sepsis is related to mortality. Crit Care Med 28:3405-3411
34. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P (2004) Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 30:260-265 (Pubitemid 38253417)
35. Angstwurm MW, Dempfle CE, Spannagl M (2006) New disseminated intravascular coagulation score: a useful tool to predict mortality in comparison with Acute Physiology and Chronic Health Evaluation II and Logistic Organ Dysfunction scores. Crit Care Med 34:314-320 (quiz 328)
36. Lang T, Bauters A, Braun SL, Potzsch B, von Pape KW, Kolde HJ, Lakner M (2005) Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 16:301-310 (Pubitemid 40705054)
37. Devreese K, Wijns W, Combes I, Van kerckhoven S, Hoylaerts MF (2007) Thrombin generation in plasma of healthy adults and children: chromogenic versus fluorogenic thrombogram analysis. Thromb Haemost 98:600-613 (Pubitemid 47412886)
38. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323-2329
39. Laterre PF, Levy H, Clermont G, Ball DE, Garg R, Nelson DR, Dhainaut JF, Angus DC (2004) Hospital mortality and resource use in subgroups of the recombinant human activated protein C worldwide evaluation in severe sepsis (PROWESS) trial. Crit Care Med 32:2207-2218 (Pubitemid 39491799)
40. Stegenga ME, van der Crabben SN, Blumer RM, Levi M, Meijers JC, Serlie MJ, Tanck MW, Sauerwein HP, van der Poll T (2008) Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood 112:82-89
41. Lissalde-Lavigne G, Combescure C, Muller L, Bengler C, Raillard A, Lefrant JY, Gris JC (2008) Simple coagulation tests improve survival prediction in patients with septic shock. J Thromb Haemost 6:645-653 (Pubitemid 351404932)
42. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 101:816-823